Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Hashim

Dermatology New York, NY Medical Doctor

NPI 1326466517 CMS profile 5701443

5 E 98Th St Fl 5, New York, NY 10029

Open in the dashboard

General payments

$5,548

201 records reported · program years 2019–2025

Research payments

$2,862

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Hashim of New York, NY is reported in the CMS Open Payments database as having received $5,548 across 201 general payments and $2,862 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,238 61
2024 General $1,552 58
2023 General $903 27
2022 General $532 23
2021 General $295 15
2020 General $91 2
2020 Research $2,045 1
2019 General $937 15
2019 Research $817 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Hashim
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Peter Hashim were reported at $1,238. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Peter Hashim Dermatology median Middle half National median
2019 $937 $454 $129–$1,240 $163
2020 $91 $235 $81–$756 $114
2021 $295 $377 $108–$1,108 $132
2022 $532 $514 $143–$1,391 $149
2023 $903 $607 $159–$1,674 $160
2024 $1,552 $751 $204–$1,903 $164
2025 $1,238 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,142 44 payments
  2. Pfizer Inc. $795 37 payments
  3. Janssen Biotech, Inc. $625 25 payments
  4. Genzyme Corporation $547 22 payments
  5. Incyte Corporation $318 10 payments
  6. UCB, Inc. $291 6 payments
  7. Regeneron Healthcare Solutions, Inc. $279 6 payments
  8. Novartis Pharmaceuticals Corporation $253 8 payments
  9. Lilly USA, LLC $212 9 payments
  10. Ortho Dermatologics, a division of Bausch Health US, LLC $174 2 payments
  11. Other $912 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,433 199 payments
  2. Education $115 2 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $670 26 payments
  2. CIBINQO $668 35 payments
  3. LITFULO $665 29 payments
  4. SKYRIZI $496 20 payments
  5. RINVOQ $468 21 payments
  6. DUPIXENT Immunology $401 15 payments
  7. OPZELURA $318 10 payments
  8. Bimzelx $291 6 payments
  9. DUPIXENT Inflammation And Immunology $258 5 payments
  10. EUCRISA $253 12 payments
  11. Other $1,704 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,862 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

276

Median for Micrographic Dermatologic Surgery: 314

Drug cost

$301,285

Median for Micrographic Dermatologic Surgery: $3,836

Branded share of claims

21%

Median for Micrographic Dermatologic Surgery: 1.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erivedge Vismodegib Brand 19 $125,591
Rinvoq Upadacitinib Brand 12 $74,732
Cibinqo Abrocitinib Brand 12 $62,531
Opzelura Ruxolitinib Phosphate Brand 15 $32,763
Clobetasol Propionate Generic 30 $1,768
Fluorouracil Generic 20 $1,126
Minoxidil Generic 23 $772
Hydrocortisone Generic 18 $652
Ketoconazole Generic 37 $600
Triamcinolone Acetonide Generic 54 $404

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 366 Part D prescribers listed as Micrographic Dermatologic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$104,648

Medicare's payments for the services billed

Medicare patients

174

Average age 77

Services billed

521

82 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 47%
Ischemic heart disease 30%
Diabetes 27%
Cancer 18%
Depression 18%
Atrial fibrillation 15%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
  • UCB, Inc. $291
$291 — —
DUPIXENT
  • GENZYME CORPORATION $222
  • SANOFI PASTEUR INC. $27
$249 — —
SKYRIZI
  • AbbVie, Inc. $201
$201 — —
OPZELURA
  • Incyte Corporation $135
$135 15 —
CIBINQO
  • PFIZER INC. $118
$118 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record